Patentability of Biotechnology Under the International Patent Regime: Differentiation v. Harmonisation

2014 ◽  
pp. 111-135
Author(s):  
Kshitij Kumar Singh
Keyword(s):  
International Patent

scholarly journals Technological Advances to Reduce Apis mellifera Mortality: A Bibliometric Analysis

2021 ◽  
Vol 13 (15) ◽  
pp. 8305
Author(s):  
Cristiano Ziegler ◽  
Tiago Sinigaglia ◽  
Mario Eduardo Santos Martins ◽  
Adriano Mendonça Souza
Keyword(s):  
Apis Mellifera ◽  
The United States ◽  
Mortality Data ◽  
Time Interval ◽  
International Patent Classification ◽  
Patent Classification ◽  
Honey Production ◽  
Technological Advances ◽  
International Patent ◽  
Technology Life Cycle

Bees play a fundamental role in the ecological balance of ecosystems, due to the pollination process they carry out on crops, including the production of honey. However, the mortality of bees is a significant concern; bee mortality can occur for several reasons, such as pesticides, mites, viruses, climate change, pathogens and a reduction in food resources and nests. The honey bee (Apis mellifera) is the most widely used bee for commercial pollination and honey production. Therefore, the main objective is to compare the development of patent families and article publications related to the reduction in A. meliífera mortality. Data on patent families were collected on the Orbit platform, while data on scientific articles were collected on the Scopus database, with a time interval of 1980–2019. Subsequently, the data were analyzed in order to show the main priority countries, main assignees, and main IPC (International Patent Classification) codes, an analysis of the technology life cycle and the correlation between the data of patent families and articles published. The technologies that help to decrease bee mortality showed a technological maturity rate of 27.15% for patent families data and 53.35% for data from articles published in journals. It was noticed that the principal interest regarding the reduction in A. mellifera mortality is focused on universities, mainly in the United States and China.

scholarly journals Applications of Silver Nanoparticles in Dentistry: Advances and Technological Innovation

2021 ◽  
Vol 22 (5) ◽  
pp. 2485
Author(s):  
Clara Couto Fernandez ◽  
Ana Rita Sokolonski ◽  
Maísa Santos Fonseca ◽  
Danijela Stanisic ◽  
Danilo Barral Araújo ◽  
...  
Keyword(s):  
Silver Nanoparticles ◽  
Technological Innovation ◽  
Scientific Literature ◽  
Technological Innovations ◽  
International Patent Classification ◽  
Patent Classification ◽  
International Patent ◽  
Promising Area ◽  
The Usa ◽  
Prevention Of Infections

Silver nanoparticles (AgNPs) have been successfully applied in several areas due to their significant antimicrobial activity against several microorganisms. In dentistry, AgNP can be applied in disinfection, prophylaxis, and prevention of infections in the oral cavity. In this work, the use of silver nanoparticles in dentistry and associated technological innovations was analyzed. The scientific literature was searched using PubMed and Scopus databases with descriptors related to the use of silver nanoparticles in dentistry, resulting in 90 open-access articles. The search for patents was restricted to the A61K code (International Patent Classification), using the same descriptors, resulting in 206 patents. The results found were ordered by dental specialties and demonstrated the incorporation of AgNPs in different areas of dentistry. In this context, the search for patents reaffirmed the growth of this technology and the dominance of the USA pharmaceutical industry over AgNPs product development. It could be concluded that nanotechnology is a promising area in dentistry with several applications.

scholarly journals Technological prospection of Diminazene Aceturate, an Angiotensin II Converting Enzyme activator, in front of diarrheic disorders

2020 ◽  
Vol 9 (12) ◽  
pp. e1691210755
Author(s):  
Luan Kelves Miranda de Souza ◽  
Kerolayne de Melo Nogueira ◽  
Jand Venes Rolim Medeiros
Keyword(s):  
Gastrointestinal Disease ◽  
Biological Activities ◽  
Fluid Replacement ◽  
Special Focus ◽  
Diminazene Aceturate ◽  
Oral Rehydration ◽  
International Patent ◽  
Rehydration Solution ◽  
Antidiarrheal Agent ◽  
Patent Filing

Diarrhea, which is a gastrointestinal disease, has as its main characteristic the rapid passage of gastric contents through the intestine, which leads to the loss of water and electrolytes and consequent dehydration. The most common fluid replacement is the use of oral rehydration solution (ORS) together with the use of the drug loperamide. However, the use of this medication can cause severe bacteremia followed by sepsis and even death. Currently, there is no effective pharmacological treatment for diarrhea, therefore, it is noted the importance of seeking new therapeutic targets for the treatment of this disease. Thus, the aim of the present study was to conduct a research on the biological activities already described for Diminazene Aceturate with a special focus on antidiarrheal agents. For this, a survey was carried out, through patent filing searches, in the USPTO, EPO, WIPO and INPI databases, using keywords and Boolean operators. Thus, it was found in the international patent databases the number of documents referring to the use of Diminazene Aceturate in several areas, mainly in the pharmaceutical industry, but with a relatively low number of documents regarding the description of possible antidiarrheal action of the compound under study , which reinforces the innovative character of research involving the use of Diminazene Aceturate as an antidiarrheal agent.

scholarly journals Technological prospection: the genus Mikania in therapeutic use

2021 ◽  
Vol 10 (14) ◽  
pp. e333101422076
Author(s):  
Nathália Andrezza Carvalho de Souza ◽  
Victória Laysna dos Anjos Santos ◽  
Tarcísio Cícero de Lima Araújo ◽  
Pedrita Alves Sampaio ◽  
Renata Rivelli Menezes de Souza ◽  
...  
Keyword(s):  
Biological Activities ◽  
The United States ◽  
World Intellectual Property Organization ◽  
European Patent ◽  
Industrial Property ◽  
Patent Classification ◽  
Innovation Research ◽  
Technological Potential ◽  
International Patent

The genus Mikania (Asteraceae) comprises about 450 species of these, 203 are found in Brazil and present several chemical and biological activities. Considering the variety of species and their therapeutic properties, the present study aimed to perform technological prospecting of this genus, since this approach aims to contribute to technological, scientific and innovation research. For this purpose, the patent documents were analyzed, regarding the applicant countries, year of filing and the international classification of patents of the genus Mikania. The search was conducted in the databases World Intellectual Property Organization (WIPO), European Patent Office (EPO) and the National Institute of Industrial Property (INPI) in October 2020, using the descriptor “Mikania”; present in the title and/or abstract in addition, documents that included medicinal approaches were selected. Thus, taking into consideration the filing countries, Japan, Brazil and the United States led the patent deposits, with the first document filed in 1991 and the largest number of applications in the years 2000 and 2010. The data concerning the international patent classification are concentrated in subclass A61K, which deals with preparations for medical, dental or hygienic purposes. These results demonstrated the therapeutic and technological potential of the Mikania species and thus which can be evidenced the potential of this study.

scholarly journals Could Globalisation be Good for World Health?

1970 ◽  
Vol 1 ◽  
Author(s):  
Thomas Pogge
Keyword(s):  
Disease Burden ◽  
Pharmaceutical Innovation ◽  
World Health ◽  
Medical Treatments ◽  
Alternative Scheme ◽  
International Patent ◽  
Good For ◽  
The Impact ◽  
Perverse Effect ◽  
Global Disease Burden

Every day thousands of people die from poverty-related causes. Many of these deaths could be avoided if appropriate medical treatments were available to the world’s poor. Due to the current tructure of the international patent regime, they are not. Since the risks and costs associated with pharmaceutical innovation are extremely high, to incentivise research, inventor firms are granted a temporary monopoly over newly invented drugs. While allowing firms to make up for the costs of research, this has the morally perverse effect of raising the prices of pharmaceuticals to a level where they become unaffordable to the world’s poor. To correct this grievous flaw, the paper proposes a concrete and realistic alternative scheme which, by rewarding medical innovators in proportion to the impact of their drugs on the global disease burden, would incentivise the production and selling of crucial drugs for the world’s poor at prices accessible to them.

Sign in / Sign up

Export Citation Format

Share Document